Sparks - Elicera Therapeutics

Elicera Therapeutics has announced preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA trial. CARMA is assessing the company’s proprietary iTANK-armed CAR T-cell therapy, ELC-301, in patients with relapsed or refractory B-cell lymphoma. The first dose cohort included three patients treated with the lowest dose, equivalent to one-tenth of the planned maximum dose. Encouragingly, two of three treated patients show no active lymphoma on specialised scans, achieving a complete metabolic response.

The Phase I/IIa CARMA trial continues to enrol patients at escalating dose levels to further evaluate safety, tolerability and preliminary efficacy. The second cohort has already been initiated, with two patients treated so far at a dose level three times higher than that of the first cohort.